Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.
1. India’s Health Ministry has issued a draft notification proposing revisions to blood product testing requirements. It proposes that products must comply with standards in the Indian Pharmacopoeia, or where unavailable, the United States or British Pharmacopoeia, and removes the requirement to test final products for HIV-I, HIV-II, Hepatitis B surface antigen, and Hepatitis C antibodies.
Source: short-url.org/1lAp8
2. The Central Drugs Standard Control Organisation (CDSCO) has enabled online submission of applications for licences to manufacture recombinant deoxyribonucleic acid based drugs under Forms 28D and 28DA through the Online National Drugs Licensing System (SUGAM portal). From 10 March 2026, the regulator will no longer accept physical applications.
Source: short-url.org/1qJFy
3. The 93rd meeting of the Drugs Technical Advisory Board (DTAB), held on 16 February 2026, reviewed key technical and regulatory matters under the Drugs and Cosmetics Act and Rules. The board discussed policy recommendations, regulatory amendments, and technical issues affecting pharmaceuticals, biologics, and medical products, guiding future regulatory updates.
Source: short-url.org/1qJFF
4. India’s Telangana Drugs Control Administration has launched a bulk SMS alert system to instantly notify pharmacies and wholesalers about Not of Standard Quality (NSQ) drugs, enabling rapid recalls of sub standard drugs, strengthening regulatory monitoring, supply-chain transparency, and patient safety across the state’s pharmaceutical market.
Source: short-url.org/1lApq
5. The Technology Development Board of Government of India has extended financial support to commercialise a rapid diagnostic kit for childhood diarrhea, aimed at enabling faster detection of infections in paediatric patients.
Source: short-url.org/1lApu